

eTable 1

Ethnicity	Country	Method	LRP4+ patients					Ref	
			AChR+	Musk+	Unspecified	dsMG	OD		
Europeans / Caucasians	Italy	I-CBA	0/16	0/7	/	0/59	0/60	Damato V; 2022	
Asian	China	CBA (protocol not specified)	3/1624 (0.18%)	0/82	/	13/455 (2.85%)	/	Li M; 2019	
Europeans / Caucasians	Germany	I-CBA and f-CBA (pfa and formalin)	/	0/10	/	7/13 (53.84%)	/	Pevzner A; 2012	
/	United States	commercial f-CBA	/	/	/	0/49	5/55 (9.09%)	Klein CJ; 2022	
Asian	Japan	LUCIP	0/100	3/28 (10.71%)	/	6/272 (2.2%)	0/101	Higuchi O; 2011	
/	United States	ELISA	/	/	/	24/181 (13.2%)	/	Rivner MH; 2020	
/	Grecia; Georgia; United States	ELISA	0/61	1/36 (2.77%)	/	11/120 (9.16%)	2/76 (2.63%)	Zhang B; 2012	
Europeans / Caucasians	Norway	mf-CBA	0/2	0/2	/	3/43 (6.97%)	/	Zisimopoulou P; 2014	
Europeans / Caucasians	The Netherlands	mf-CBA	/	/	/	8/31 (25.8%)	/		
Europeans / Caucasians	Poland	mf-CBA	1/29 (3.44%)	0/5	/	19/58 (32.75%)	/		
Europeans / Caucasians	France	mf-CBA	0/6	1/3 (33.33%)	/	13/82 (15.85%)	/		
Europeans / Caucasians	Italy	mf-CBA	0/28	0/27	/	14/66 (21.21%)	/		
Europeans / Caucasians	Serbia	mf-CBA	7/23 (30.43%)	3/18 (16.66%)	/	7/45 (15.55%)	/		
Europeans / Caucasians	Grece	mf-CBA	0/19	1/7 (14.28%)	/	29/106 (27.35%)	4/110 (3.63%)		
Europeans / Caucasians	Cyprus	mf-CBA	/	5/5 (100%)	/	9/64 (14.06%)	/		
Europeans / Caucasians	Turkey	mf-CBA	/	/	/	5/69 (7.24%)	/		
Europeans / Caucasians	Israel	mf-CBA	/	/	/	12/71 (16.9%)	/		
Europeans / Caucasians	Italy	mf-CBA + flow cytofluorimetric analysis	3/23 (13.04%)	3/23 (13.04%)	/	8/55 (14.54%)	/		Marino M; 2015
/	Greece/Italy	mf-CBA and RIPA	1/40 (2.5%)	/	/	/	24/104 (23.07%) (ALS); 4/84 (4.76%) (Multiple sclerosis)		Tzartos JS; 2014
/	Korea	in house f-CBA (PFA fixed)	0/134	0/15	/	3/53 (5.66%)	0/38 (other neuromuscular disorders)		Chung HY; 2023
/	USA	Commercial f-CBA	/	/	0/31	0/43	8/220 (3.63%) (4/8 ALS, 4 other neuromuscular disorders)	Heber M; 2023	
/	USA	ELISA	/	/	/	/	8/82 (9.75%)	Rivner MH; 2017	
Asian	China	mf-CBA	/	/	1/65 (1.53%)	/	3/56 (5.35%) ALS ; 0/60 other neuroimmun disorders	Lei L; 2019	
/	Greece/USA	ELISA (CBA to precipitate the antibodies)	0/61	1/36 (2.77%)	/	11/120 (55%)	2/16 (12.5%) (NMOSD)	Tzartos JS; 2012	
African	South Africa	I-CBA	/	/	/	0/53	/	Huda S; 2016	
Miscellaneous	UK	I-CBA	/	/	/	0/21	/	Rodríguez Cruz PM; 2015	

References

1. Chung HY, Kim MJ, Kim SW, Oh J, Shin HY. Development and Application of a Cell-Based Assay for LRP4 Antibody Associated With Myasthenia Gravis. *J Clin Neurol*. 2023;19:60.
2. Damato V, Spagni G, Monte G, et al. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. *J Neurol Neurosurg Psychiatry*. 2022;93:995–1000.
3. Heber M, Li Y. Caution on LRP4 antibody results in patients being evaluated for myasthenia gravis. *Journal of Neuroimmunology*. 2023;377:578063.
4. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. *Annals of Neurology*. 2011;69:418–422.
5. Huda S, Woodhall MR, Vincent A, Heckmann JM. Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort. *Muscle and Nerve*. 2016;54:1023–1029.
6. Klein CJ, Beecher G, Lamb C, et al. LRP4-IgG service line testing in seronegative myasthenia gravis and controls. *Journal of Neuroimmunology*. 2022;368:577895.
7. Li M, Han J, Zhang Y, et al. Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis. *Eur J Neurol*. 2019;26:1296.
8. Li Z, Zhang C, Chang T, et al. A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study. *The Lancet Regional Health - Western Pacific*. 2023;38:100846.
9. Marino M, Scuderi F, Samengo D, et al. Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis. *PLoS ONE*. 2015;10:e0135378.
10. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. *J Neurol*. 2012;259:427–435.
11. Rivner MH, Liu S, Quarles B, et al. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients: Short Reports. *Muscle Nerve*. 2017;55:430–432.
12. Rivner MH, Quarles BM, Pan J, et al. Clinical features of LRP4 /agrin-antibody-positive myasthenia gravis: A multicenter study. *Muscle and Nerve*. 2020;62:333–343.
13. Rodríguez Cruz PM, Al-Hajjar M, Huda S, et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. *JAMA Neurol*. 2015;72:642.
14. Tzartos JS, Zisimopoulou P, Rentzos M, et al. LRP 4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. *Ann Clin Transl Neurol*. 2014;1:80–87.
15. Tzartos JS, Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia Gravis. *Arch Neurol*. 2012;69:445.

16. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia Gravis. *Archives of Neurology*. 2012;69:445–451.
17. Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. *Journal of Autoimmunity*. 2014;52:139–145.